🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re excited to share the formation of our Clinical Scientific Advisory Board (SAB) with leading experts in drug development and #cardiometabolic diseases. Their insights will drive progress in our cardioendrocrine programs. Learn more: businesswire.com/news/home/2025…

It's American Heart Month. Heart disease remains the biggest killer in the US, taking 700K lives each year. We are committed to developing next-generation therapies for people living with cardioendocrine diseases, like #heartdisease. Know the steps that help protect #ourhearts.

As February wraps up, remember that your heart health is a year-round effort. Undiagnosed or untreated high LDL & remnant cholesterol can lead to serious problems, such as heart attack & stroke. #Ourhearts are restless; stay informed, up-to-date, & inquisitive about your health.

Acromegaly is a life-shortening disease that is estimated to have more than 30K patients in the U.S. On Rare Disease Day, we recognize that life is different for people living with rare diseases. That’s why we remain committed to better understand and treat #acromegaly.

At Marea, we’re harnessing breakthroughs in human genetics & cutting-edge data science to revolutionize treatment for cardioendocrine diseases. We are developing precise, targeted therapies to address the root cause of dysfunction to deliver better outcomes to those who need them

CEO Josh Lehrer will present at Piper Sandler's 2nd Annual Virtual Cardio Day, featuring key takeaways from industry leaders to discuss the latest in #cardiovascular research. We look forward to sharing our progress & insights as we continue to drive innovation in

We’re excited to be recognized as a 2025 #BestPlacetoWork in the Bay Area by San Francisco Business Times & Silicon Valley Business Journal. Tackling cardiometabolic & endocrine disease takes more than cutting-edge science—it takes a team that’s authentic, resilient, audacious, and humble at its core. We’re

Marea Therapeutics leadership will be engaging with the investment community with Needham and Piper Sandler. We look forward to connecting with investors and sharing our strategic vision for advancing #cardioendocrine innovation.

We believe the best work happens in the right environment, where challenge meets support & inspiration, so being named a San Francisco Business Times & @SVBizJournal #BPTW means so much to us. We're driven by curiosity, fueled by impact, & united in transforming the future of

We are pleased to share that two abstracts on our lead program, MAR001, will be presented at the 93rd European Atherosclerosis Society Congress next month. Details: businesswire.com/news/home/2025…

Following our announcement yesterday of our #EASCongress2025 late-breaker presentation for MAR001, our ANGPTL4 inhibitor, Marea Co-founder & CSO Ethan J. Weiss & CEO Josh Lehrer sat down with BiotechTV's Brad Loncar. Listen below as they break down the approach behind MAR001

As Marea grows & evolves, we’re thrilled to move into a new space! Our new office isn’t just a new location; it’s a hub for collaboration, creativity, & #innovation. Designed for the future, it reflects our ambition to push the boundaries of #cardioendocrine diseases. We can’t

We leverage precision medicine to pinpoint disease drivers and identify targeted patient populations for more effective treatments. By designing trials around validated biomarkers, we accelerate development to bring life-changing therapies to patients faster.

Today, we presented positive data from the Phase 2a clinical trial of MAR001 in a late-breaking oral session at the #EASCongress2025. These data validate the ability of MAR001 to significantly lower remnant cholesterol and triglycerides by inhibiting ANGPTL4. We look forward to

Following the #EASCongress2025, we’re pleased to share that Phase 2a and preclinical data from our MAR001 program have been published in The Lancet and eBioMedicine – The Lancet Discovery Science, respectively. A sincere thank you to the Marea team members, clinical trial investigators and patients who have

We are pleased to announce the appointment of Charmi Turner as SVP, People & Culture. Her human resources expertise in the life sciences industry will be essential in enhancing leadership development and organizational alignment at Marea as we advance the clinical development of

CEO Josh Lehrer & CFO Ian Clements will attend the annual Jefferies Global Healthcare Conference next week. We look forward to sharing more about our clinical-stage pipeline of novel therapies to address genetically-validated drivers of #cardioendocrine diseases.

CDO Rebecca Juliano, Ph.D., will join the 2025 #NLASessions for an encore presentation of our MAR001 Phase 2a data. This ANGPTL4-targeting antibody showed up to a 52.7% reduction in triglycerides and 66.0% reduction in remnant #cholesterol in patients with elevated baseline

Marea co-founders Josh Lehrer & Ethan J. Weiss joined Luke Timmerman on The Long Run podcast to share insights into our unique approach to tackling #cardiometabolic diseases and what it takes to build a company around a game-changing idea. Tune in below. timmermanreport.com/2025/05/a-new-…